Viewing Study NCT01995708



Ignite Creation Date: 2024-05-06 @ 2:12 AM
Last Modification Date: 2024-10-26 @ 11:15 AM
Study NCT ID: NCT01995708
Status: COMPLETED
Last Update Posted: 2024-02-09
First Post: 2013-11-20

Brief Title: CT7 MAGE-A3 and WT1 mRNA-electroporated Autologous Langerhans-type Dendritic Cells as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Sponsor: Memorial Sloan Kettering Cancer Center
Organization: Memorial Sloan Kettering Cancer Center

Study Overview

Official Title: A Phase I Trial of Vaccination With CT7 MAGE-A3 and WT1 mRNA-electroporated Autologous Langerhans-type Dendritic Cells as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Status: COMPLETED
Status Verified Date: 2022-06
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The purpose of this study is to see if the investigator can help the immune system to work against myeloma

This study will see if a vaccine made with altered dendritic cells will make T cells work against tumor cells The stem cells collected for the transplant will also be used to grow dendritic cells in the lab The dendritic cells will carry the antigens These cells then will be injected under the skin The investigators will do lab studies before and after the vaccination to find out if the vaccine is working
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None